Published in J Hematol Oncol on April 23, 2011
Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer (2012) 1.47
The fat side of prostate cancer. Biochim Biophys Acta (2013) 1.46
Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer (2014) 1.22
Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J Cell Biochem (2013) 0.94
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol (2012) 0.93
Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity. PLoS One (2013) 0.88
Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. J Hematol Oncol (2014) 0.82
Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect Comparison. Clin Med Insights Oncol (2014) 0.79
Novel epigenetic target therapy for prostate cancer: a preclinical study. PLoS One (2014) 0.77
Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy. Prostate Cancer (2016) 0.75
Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation. Oncotarget (2016) 0.75
Complete radiologic response in metastatic castration-resistant prostate cancer treated with cabazitaxel. Iran J Med Sci (2015) 0.75
miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth. Oncotarget (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02
The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 6.67
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol (2009) 2.88
Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell (2009) 2.85
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab (2008) 1.78
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol (2009) 1.40
Cabazitaxel. Nat Rev Drug Discov (2010) 1.34
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol (2010) 1.27
Update on tubulin-binding agents. Pathol Biol (Paris) (2006) 1.26
Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs (2010) 1.23
Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc (2007) 1.22
Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res (2009) 1.16
Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev (2006) 1.04
Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist (2009) 1.00
Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. Future Oncol (2010) 0.82
Docetaxel treatment in the elderly patient with hormone refractory prostate cancer. Clin Interv Aging (2007) 0.81
ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Investig Drugs (2008) 0.81
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. Ann Oncol (2009) 0.81
Zibotentan for the treatment of castrate-resistant prostate cancer. Expert Opin Investig Drugs (2010) 0.78